Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Reata Pharmaceuticals, Inc. (RETA) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,749.74 | 872.21 | 208.87 | 193.89 | 42.54 | 0.00 | 8.5233 | -0.35 | -0.9925 | -23.1722 | -0.09 | -0.10 | 7.2047 | - - | ||
| Maximum | - - | - - | - - | 445,233.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 701.8537 | 6.70 | 3.0051 | 85.3485 | 0.15 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Krystal Biotech, Inc. KRYS | 181.95 | 3.85 2.16% | 48 vs. 225 | 5,232.00 | 45.00 | 0.00 | 14.00 | -268.00 | 0.0300 | 1336.3467 | 0.0000 | 0.9465 | 0.0206 | 0.0012 | 0.0011 | 12.2870 | 28.00 | ||
| Vir Biotechnology, Inc. VIR | 6.78 | 0.04 0.59% | 1,254 vs. 995 | 933.00 | 56.00 | -65.00 | -111.00 | -303.00 | -0.4800 | -5.2847 | 0.0000 | 0.9188 | -1.1579 | -0.0422 | -0.0364 | 12.4686 | 137.00 | ||
| Reata Pharmaceuticals, Inc. RETA | 172.36 | 0.04 0.02% | 1,909 vs. 954 | 6,566.00 | 22.00 | 192.00 | -70.00 | -1,490.00 | 5.1200 | 5.4820 | 0.0000 | 0.9628 | 8.4849 | 2.2110 | 0.3840 | 2.8209 | 38.00 | ||
| CureVac N.V. CVAC | 2.56 | 0.07 2.61% | 167 vs. 473 | 573.00 | 12.00 | -70.00 | -101.00 | -1,636.00 | -0.3100 | -2.2038 | 0.0000 | -2.3694 | -5.7022 | -0.1579 | -0.1022 | 2.0371 | 224.00 | ||
| Sarepta Therapeutics, Inc. SRPT | 110.61 | -0.25 -0.22% | 375 vs. 864 | 10,565.00 | 413.00 | 36.00 | -284.00 | -4,410.00 | 0.3800 | 83.5325 | 0.0000 | 0.8777 | 0.0874 | 0.0376 | 0.0112 | 2.9737 | 95.00 | ||
| PTC Therapeutics, Inc. PTCT | 43.00 | 1.04 2.48% | 268 vs. 714 | 3,316.00 | 210.00 | -91.00 | 6.00 | -3,375.00 | -1.2000 | -5.9705 | 0.0000 | 0.6846 | -0.4358 | 0.1024 | -0.0512 | 1.8854 | 77.00 | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 326.62 | 9.54 3.01% | 160 vs. 376 | 7,123.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Akero Therapeutics, Inc. AKRO | 31.16 | 0.53 1.71% | 135 vs. 551 | 2,174.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.